Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Introduction: RRDLBCL outcomes remain poor despite autologous transplant and CAR-T therapies offering potential cure to a minority. Evidence for current therapies is mostly from phase II trials with stringent eligibility criteria. Applicability to real-world populations is poorly understood. PolaBR efficacy in RR DLBCL was shown in the landmark GO29365 study (BCT02600897; Sehn Blood Adv 2022).
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
